Hanmi-Sanofi, First ‘ARB-Statin’ FDC new drug approval
(The Yakup Shinmoon)
The fixed dose combination (FDC) of hypertension drug Irbesratan and hyperlipidemia drug Atorvastatin get approved to sell in Korea first ever.
Hanmi and Sanofi revealed on the November 7 that the marke...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
